{"id":62169,"date":"2026-04-02T12:54:25","date_gmt":"2026-04-02T04:54:25","guid":{"rendered":"https:\/\/flcube.com\/?p=62169"},"modified":"2026-04-02T12:54:26","modified_gmt":"2026-04-02T04:54:26","slug":"chinas-nmpa-unveils-ambitious-ai-drug-regulation-roadmap-through-2035","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62169","title":{"rendered":"China&#8217;s NMPA Unveils Ambitious &#8220;AI + Drug Regulation&#8221; Roadmap Through 2035"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> today released its comprehensive <strong>&#8220;Implementation Opinions on &#8216;AI + Drug Regulation'&#8221;<\/strong>, outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-timeline-amp-objectives\">Strategic Timeline &amp; Objectives<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Year<\/th><th>Key Deliverables<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Framework<\/strong><\/td><td>2030<\/td><td>Integrated innovation system combining drug regulation and AI; basic operational management mechanism; enhanced computing infrastructure<\/td><\/tr><tr><td><strong>Mature Ecosystem<\/strong><\/td><td>2035<\/td><td>New paradigm for intelligent drug safety governance that is digitally driven, intelligent and agile, autonomous and controllable, and ecologically synergetic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-ai-infrastructure-development\">Core AI Infrastructure Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Computing Infrastructure<\/strong>: More integrated and efficient systems to support regulatory AI applications<\/li>\n\n\n\n<li><strong>High-Quality Datasets<\/strong>: Curated data repositories specifically designed for pharmaceutical regulatory use cases<\/li>\n\n\n\n<li><strong>Vertical Large Models<\/strong>: Specialized AI models trained on pharmaceutical regulatory data and requirements<\/li>\n\n\n\n<li><strong>Intelligent Agents<\/strong>: Autonomous systems tailored to meet specific intelligent regulation needs across the drug lifecycle<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-application-scenarios-amp-implementation-roadmap\">Application Scenarios &amp; Implementation Roadmap<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-r-amp-d-stage-implementation\">R&amp;D Stage Implementation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Trial Data Standardization<\/strong>: Enhanced governance frameworks for clinical trial data<\/li>\n\n\n\n<li><strong>Technical Guidelines Development<\/strong>:<\/li>\n\n\n\n<li>Electronic clinical trial records standards<\/li>\n\n\n\n<li>Computer system validation guidelines<\/li>\n\n\n\n<li>Refined technical guidance system leveraging clinical trial big data<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-manufacturing-stage-implementation\">Manufacturing Stage Implementation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Risk Product Focus<\/strong>: Enhanced digital oversight for vaccines, blood products, and controlled substances<\/li>\n\n\n\n<li><strong>Hybrid Inspection Model<\/strong>: Integration of on-site inspections with off-site supervision<\/li>\n\n\n\n<li><strong>Risk Monitoring Agents<\/strong>: AI-powered systems analyzing real-time manufacturer data including:<\/li>\n\n\n\n<li>Production process surveillance videos<\/li>\n\n\n\n<li>Process images<\/li>\n\n\n\n<li>IoT sensor data<\/li>\n\n\n\n<li><strong>Dynamic Risk Monitoring<\/strong>: Real-time quality and safety risk assessment during production<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-distribution-amp-use-stage-implementation\">Distribution &amp; Use Stage Implementation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Traceability System Upgrade<\/strong>: Digital and intelligent enhancement of existing drug traceability infrastructure<\/li>\n\n\n\n<li><strong>Stakeholder Responsibilities<\/strong>:<\/li>\n\n\n\n<li>Pharmaceutical companies: Strengthened traceability accountability<\/li>\n\n\n\n<li>Platform companies: Enhanced technical support and service capabilities<\/li>\n\n\n\n<li><strong>Universal Coding<\/strong>: Accelerated assignment of traceability codes to all marketed product variants<\/li>\n\n\n\n<li><strong>End-to-End Visibility<\/strong>: Complete traceability from manufacturing through distribution to final use<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-expected-impact-amp-efficiency-gains\">Expected Impact &amp; Efficiency Gains<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Human-Machine Collaboration<\/strong>: Significantly improved efficiency in regulatory processes<\/li>\n\n\n\n<li><strong>Full-Lifecycle Intelligence<\/strong>: Enhanced digital and intelligent regulatory capabilities across all stages<\/li>\n\n\n\n<li><strong>Risk-Based Oversight<\/strong>: Proactive identification and mitigation of quality and safety risks<\/li>\n\n\n\n<li><strong>Regulatory Agility<\/strong>: Faster response to emerging challenges through AI-enabled decision support<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding NMPA&#8217;s AI integration timeline, infrastructure development, and regulatory transformation objectives. Actual implementation may vary based on technological advancement, resource allocation, and evolving regulatory priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-806aab00-1a56-4c17-89d9-6824a136db3c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u56fd\u5bb6\u836f\u76d1\u5c40\u53d1\u5e03\u300a\u5173\u4e8e\u4eba\u5de5\u667a\u80fd-\u836f\u54c1\u76d1\u7ba1\u7684\u5b9e\u65bd\u610f\u89c1\u300b.doc\">\u56fd\u5bb6\u836f\u76d1\u5c40\u53d1\u5e03\u300a\u5173\u4e8e\u201c\u4eba\u5de5\u667a\u80fd \u836f\u54c1\u76d1\u7ba1\u201d\u7684\u5b9e\u65bd\u610f\u89c1\u300b<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u56fd\u5bb6\u836f\u76d1\u5c40\u53d1\u5e03\u300a\u5173\u4e8e\u4eba\u5de5\u667a\u80fd-\u836f\u54c1\u76d1\u7ba1\u7684\u5b9e\u65bd\u610f\u89c1\u300b.doc\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-806aab00-1a56-4c17-89d9-6824a136db3c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) today released its comprehensive &#8220;Implementation Opinions on &#8216;AI +&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-62169","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NMPA Unveils Ambitious &quot;AI + Drug Regulation&quot; Roadmap Through 2035 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) today released its comprehensive &quot;Implementation Opinions on &#039;AI + Drug Regulation&#039;&quot;, outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62169\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NMPA Unveils Ambitious &quot;AI + Drug Regulation&quot; Roadmap Through 2035\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) today released its comprehensive &quot;Implementation Opinions on &#039;AI + Drug Regulation&#039;&quot;, outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62169\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T04:54:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T04:54:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NMPA Unveils Ambitious &#8220;AI + Drug Regulation&#8221; Roadmap Through 2035\",\"datePublished\":\"2026-04-02T04:54:25+00:00\",\"dateModified\":\"2026-04-02T04:54:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62169#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62169\",\"name\":\"China's NMPA Unveils Ambitious \\\"AI + Drug Regulation\\\" Roadmap Through 2035 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-02T04:54:25+00:00\",\"dateModified\":\"2026-04-02T04:54:26+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) today released its comprehensive \\\"Implementation Opinions on 'AI + Drug Regulation'\\\", outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62169\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62169#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NMPA Unveils Ambitious &#8220;AI + Drug Regulation&#8221; Roadmap Through 2035\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NMPA Unveils Ambitious \"AI + Drug Regulation\" Roadmap Through 2035 - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) today released its comprehensive \"Implementation Opinions on 'AI + Drug Regulation'\", outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62169","og_locale":"en_US","og_type":"article","og_title":"China's NMPA Unveils Ambitious \"AI + Drug Regulation\" Roadmap Through 2035","og_description":"China's National Medical Products Administration (NMPA) today released its comprehensive \"Implementation Opinions on 'AI + Drug Regulation'\", outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.","og_url":"https:\/\/flcube.com\/?p=62169","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-02T04:54:25+00:00","article_modified_time":"2026-04-02T04:54:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62169#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62169"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NMPA Unveils Ambitious &#8220;AI + Drug Regulation&#8221; Roadmap Through 2035","datePublished":"2026-04-02T04:54:25+00:00","dateModified":"2026-04-02T04:54:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62169"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62169#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62169","url":"https:\/\/flcube.com\/?p=62169","name":"China's NMPA Unveils Ambitious \"AI + Drug Regulation\" Roadmap Through 2035 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-02T04:54:25+00:00","dateModified":"2026-04-02T04:54:26+00:00","description":"China's National Medical Products Administration (NMPA) today released its comprehensive \"Implementation Opinions on 'AI + Drug Regulation'\", outlining a strategic framework to transform pharmaceutical oversight through artificial intelligence integration across the entire product lifecycle by 2035.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62169#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62169"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62169#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NMPA Unveils Ambitious &#8220;AI + Drug Regulation&#8221; Roadmap Through 2035"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62169"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62169\/revisions"}],"predecessor-version":[{"id":62171,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62169\/revisions\/62171"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}